395 related articles for article (PubMed ID: 22541434)
1. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.
Kumar MS; Hancock DC; Molina-Arcas M; Steckel M; East P; Diefenbacher M; Armenteros-Monterroso E; Lassailly F; Matthews N; Nye E; Stamp G; Behrens A; Downward J
Cell; 2012 Apr; 149(3):642-55. PubMed ID: 22541434
[TBL] [Abstract][Full Text] [Related]
2. GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer.
Tessema M; Yingling CM; Snider AM; Do K; Juri DE; Picchi MA; Zhang X; Liu Y; Leng S; Tellez CS; Belinsky SA
J Thorac Oncol; 2014 Jun; 9(6):784-93. PubMed ID: 24807155
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
[TBL] [Abstract][Full Text] [Related]
4. Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Steckel M; Molina-Arcas M; Weigelt B; Marani M; Warne PH; Kuznetsov H; Kelly G; Saunders B; Howell M; Downward J; Hancock DC
Cell Res; 2012 Aug; 22(8):1227-45. PubMed ID: 22613949
[TBL] [Abstract][Full Text] [Related]
5. MutT Homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways.
Patel A; Burton DG; Halvorsen K; Balkan W; Reiner T; Perez-Stable C; Cohen A; Munoz A; Giribaldi MG; Singh S; Robbins DJ; Nguyen DM; Rai P
Oncogene; 2015 May; 34(20):2586-96. PubMed ID: 25023700
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Sunaga N; Shames DS; Girard L; Peyton M; Larsen JE; Imai H; Soh J; Sato M; Yanagitani N; Kaira K; Xie Y; Gazdar AF; Mori M; Minna JD
Mol Cancer Ther; 2011 Feb; 10(2):336-46. PubMed ID: 21306997
[TBL] [Abstract][Full Text] [Related]
7. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
8. Scrib heterozygosity predisposes to lung cancer and cooperates with KRas hyperactivation to accelerate lung cancer progression in vivo.
Elsum IA; Yates LL; Pearson HB; Phesse TJ; Long F; O'Donoghue R; Ernst M; Cullinane C; Humbert PO
Oncogene; 2014 Nov; 33(48):5523-33. PubMed ID: 24276238
[TBL] [Abstract][Full Text] [Related]
9. Contributions of KRAS and RAL in non-small-cell lung cancer growth and progression.
Guin S; Ru Y; Wynes MW; Mishra R; Lu X; Owens C; Barn AE; Vasu VT; Hirsch FR; Kern JA; Theodorescu D
J Thorac Oncol; 2013 Dec; 8(12):1492-501. PubMed ID: 24389431
[TBL] [Abstract][Full Text] [Related]
10. Reconstructing targetable pathways in lung cancer by integrating diverse omics data.
Balbin OA; Prensner JR; Sahu A; Yocum A; Shankar S; Malik R; Fermin D; Dhanasekaran SM; Chandler B; Thomas D; Beer DG; Cao X; Nesvizhskii AI; Chinnaiyan AM
Nat Commun; 2013; 4():2617. PubMed ID: 24135919
[TBL] [Abstract][Full Text] [Related]
11. Ran is a potential therapeutic target for cancer cells with molecular changes associated with activation of the PI3K/Akt/mTORC1 and Ras/MEK/ERK pathways.
Yuen HF; Chan KK; Grills C; Murray JT; Platt-Higgins A; Eldin OS; O'Byrne K; Janne P; Fennell DA; Johnston PG; Rudland PS; El-Tanani M
Clin Cancer Res; 2012 Jan; 18(2):380-91. PubMed ID: 22090358
[TBL] [Abstract][Full Text] [Related]
12. Ras effector mutant expression suggest a negative regulator inhibits lung tumor formation.
Vandal G; Geiling B; Dankort D
PLoS One; 2014; 9(1):e84745. PubMed ID: 24489653
[TBL] [Abstract][Full Text] [Related]
13. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer.
Molina-Arcas M; Hancock DC; Sheridan C; Kumar MS; Downward J
Cancer Discov; 2013 May; 3(5):548-63. PubMed ID: 23454899
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells.
Moran DM; Trusk PB; Pry K; Paz K; Sidransky D; Bacus SS
Mol Cancer Ther; 2014 Jun; 13(6):1611-24. PubMed ID: 24688052
[TBL] [Abstract][Full Text] [Related]
15. Impaired AKT signaling and lung tumorigenesis by PIERCE1 ablation in KRAS-mutant non-small cell lung cancer.
Roh JI; Lee J; Sung YH; Oh J; Hyeon DY; Kim Y; Lee S; Devkota S; Kim HJ; Park B; Nam T; Song Y; Kim Y; Hwang D; Lee HW
Oncogene; 2020 Sep; 39(36):5876-5887. PubMed ID: 32728173
[TBL] [Abstract][Full Text] [Related]
16. The genetics and biology of KRAS in lung cancer.
Westcott PM; To MD
Chin J Cancer; 2013 Feb; 32(2):63-70. PubMed ID: 22776234
[TBL] [Abstract][Full Text] [Related]
17. Co-dependency of PKCĪ“ and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Ohm AM; Tan AC; Heasley LE; Reyland ME
Oncogene; 2017 Jul; 36(30):4370-4378. PubMed ID: 28368426
[TBL] [Abstract][Full Text] [Related]
18. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis.
Mortazavi F; Lu J; Phan R; Lewis M; Trinidad K; Aljilani A; Pezeshkpour G; Tamanoi F
BMC Cancer; 2015 May; 15():381. PubMed ID: 25956913
[TBL] [Abstract][Full Text] [Related]
19. Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival.
Meyer SE; Hasenstein JR; Baktula A; Velu CS; Xu Y; Wan H; Whitsett JA; Gilks CB; Grimes HL
Am J Pathol; 2010 Sep; 177(3):1503-13. PubMed ID: 20639455
[TBL] [Abstract][Full Text] [Related]
20. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
